tbuckley/cabot-search huggingface dataset:
Diagnostic microbiologique de la borréliose de Lyme à l’institut national de santé publique du Portugal (1990-2004)
Authors: I Lopes de Carvalho, M S Núncio
Journal: Eurosurveillance (2006)

La borreliose de Lyme est consideree comme une maladie emergente dans certaines regions du monde, notamment au Portugal. Le premier cas humain de borreliose de Lyme au Portugal a ete identifie en 1989. Depuis 1999, cette maladie est a declaration obligatoire au Portugal, mais seulement quelques cas sont declares chaque annee, ce qui rend peu fiables l’analyse des facteurs de risque et l’evaluation de l’impact en sante publique. Dans cette etude, les auteurs ont utilise les donnees disponibles au Centre d’etudes des vecteurs et des maladies infectieuses (CEVDI), a l’Institut national de sante publique Dr Ricardo Jorge (INSA). Ils ont analyse les donnees sur les 15 dernieres annees (1990-2004) et les ont comparees aux cas rapportes au registre national (1999-2004). Le diagnostic de laboratoire etait base sur des tests serologiques. L’annee du diagnostic, le sexe, l’âge, l’origine geographique et les symptomes cliniques sont disponibles pour 628 cas portugais positifs confirmes. Le nombre annuel de cas variait entre 2 et 78, le nombre maximum de cas ayant ete rapporte en 1997. Parmi les cas positifs, 53,5% etaient des femmes et le groupe d’âge le plus touche etait les 35-44 ans. La neuroborreliose etait la manifestation clinique la plus courante (37,3%). Des cas ont ete detectes dans 17 des 20 regions au Portugal, et le plus grand nombre de cas confirmes venait de la region de Lisbonne. La comparaison entre le nombre de cas declares et le nombre de cas confirmes positifs par notre laboratoire montre clairement une sous-notification de la borreliose de Lyme. En raison de la dispersion des cas positifs et de la faible prevalence de l’espece Ixodes ricinus, la mesure de prevention la plus efficace contre la borreliose de Lyme au Portugal reste l’education des groupes a risque sur les moyens de prevention des morsures de tiques.
Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
Authors: C. Vivaldi, E. Arrigoni, R. Morganti, S. Catanese, L. Fidilio, I. Pecora, G. Restante, L. Fornaro, S. Crucitta, M. Lencioni, E. Rofi, E. Vasile, A. Falcone, R. Danesi, M. Del Re
Journal: Annals of Oncology (2017)
Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma
Authors: A.M. Menzies, M. Gonzalez, A. Guminski, O. Nieweg, K. Shannon, J.F. Thompson, R. Kefford, S. Ch'Ng, J. Stretch, A.J. Spillane, J. Lee, H. Lee, R. Kapoor, L. Emmett, H. Rizos, R.P. Saw, R.A. Scolyer, G.V. Long
Journal: Annals of Oncology (2017)
Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial
Authors: J. Mooi, P. Wirapati, R. Asher, C. Lee, P. Savas, T.J. Price, S. Tejpar, J. Mariadason, N. Tebbutt
Journal: Annals of Oncology (2017)
Stapled anastomosis versus hand-sewn anastomosis of gastro/duodenojejunostomy in pancreaticoduodenectomy: A systematic review and meta-analysis
Authors: Shahin Hajibandeh, Shahab Hajibandeh, Rao Muhammad Asaf Khan, Sohail Malik, Moustafa Mansour, Ambareen Kausar, Daren Subar
Journal: International Journal of Surgery (2017)
Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis, and subjects without pain: a blind comparison of DSM-III diagnoses
Authors: T A Ahles, S A Khan, M B Yunus, D A Spiegel, A T Masi
Journal: American Journal of Psychiatry (1991)

The major purpose of this study was to compare the frequency of the occurrence of DSM-III diagnoses in patients with primary fibromyalgia syndrome, patients with rheumatoid arthritis, and subjects without pain.Thirty-five patients with primary fibromyalgia, 33 patients with rheumatoid arthritis, and 31 nonpatients without pain were blindly assessed for psychiatric diagnoses with the Psychiatric Diagnostic Interview.Data from this interview revealed no group differences in terms of lifetime history of any psychiatric disorders, including major depression, somatization disorder, or anxiety-based disorders. Analysis of the auxiliary symptoms of depression on the Psychiatric Diagnostic Interview revealed that the patients with fibromyalgia did not report a higher frequency of vegetative signs of depression. However, analysis of the somatization scale revealed an interaction between medical and psychiatric diagnoses: patients with primary fibromyalgia syndrome and a psychiatric history endorsed significantly more somatic symptoms than did patients with rheumatoid arthritis or subjects without pain, and fibromyalgia patients without a psychiatric history were no more likely to endorse somatic symptoms than were arthritis patients or subjects without pain.The Psychiatric Diagnostic Interview data failed to discriminate in any major way between primary fibromyalgia syndrome (a disorder with no known organic etiology) and rheumatoid arthritis (a disorder with a known organic etiology). Therefore, these data do not support a psychopathology model as a primary explanation of the symptoms of primary fibromyalgia syndrome.
Lipolysis in Brown Adipocytes Is Not Essential for Cold-Induced Thermogenesis in Mice
Authors: Hyunsu Shin, Yinyan Ma, Tatyana Chanturiya, Qiang Cao, Youlin Wang, Anil K.G. Kadegowda, Rachel Jackson, Dominic Rumore, Bingzhong Xue, Hang Shi, Oksana Gavrilova, Liqing Yu
Journal: Cell Metabolism (2017)
Usutu virus infections among blood donors, Austria, July and August 2017 – Raising awareness for diagnostic challenges
Authors: Tamás Bakonyi, Christof Jungbauer, Stephan W. Aberle, Jolanta Kolodziejek, Katharina Dimmel, Karin Stiasny, Franz Allerberger, Norbert Nowotny
Journal: Eurosurveillance (2017)

Between July and August 2017, seven of 12,047 blood donations from eastern Austria, reacted positive to West Nile virus (WNV) in the cobas test (Roche). Follow-up investigations revealed Usutu virus (USUV) nucleic acid in six of these. Retrospective analyses of four blood donors diagnosed as WNV-infected in 2016 showed one USUV positive. Blood transfusion services and public health authorities in USUV-endemic areas should be aware of a possible increase of human USUV infections.
Monitoring HIV prevalence and behaviour of men who have sex with men in Barcelona, Spain
Authors: K Pérez, A Rodes, J Casabona Barbarà
Journal: Eurosurveillance (2002)

Recently, different studies among men who have sex with men (MSMs) have reported an increase in HIV incidence and sexually transmitted infections, and an increase in sexual risk behaviour. But the optimism regarding anti-retroviral treatments may lead to a greater relaxation in protective measures in the near future.
Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): Incidence and impact on quality of life
Authors: A. Lamarca, L. McCallum, C. Nuttall, J. Barriuso, M. Frizziero, R. Leon, W. Mansoor, M.G. McNamara, R.A. Hubner, J.W. Valle
Journal: Annals of Oncology (2017)
Epidemiologia da infecção por Mycoplasma pneumoniae na Polónia: 28 anos de vigilância em Varsóvia, 1970-1997
Authors: W Rastawicki, S Kaluzewski, M Jagielski, R Gierczyski
Journal: Eurosurveillance (1998)

O Mycoplasma pneumoniae e uma causa comum de doenca do tracto respiratorio inferior no homem, particularmente entre as criancas mais velhas, adolescentes e jovens adultos. A infeccao e endemica nas cidades e tem sido observadas alguns aumentos epidemicos em intervalos de 4 a 7 anos. O M. pneumoniae cresce lentamente e a sua cultura e dificil e demorada. Deste modo, o diagnostico das infeccoes por M. pneumoniae e geralmente baseado na serologia – principalmente pelos testes de fixacao do complemento (TFC) (1,2).
Necesidad de homogeneizar los protocolos de manejo clínico de las exposiciones al VIH en Europa
Authors: R Tubiana
Journal: Eurosurveillance (2004)

Esta necesidad es ya antigua. Dos grupos de trabajo que reunen investigadores de un total de 14 paises han realizado importantes estudios sobre el tema. Sus conclusiones y recomendaciones se recogen en sendos articulos de Jesus Almeda et al y Vincenzo Puro et al [1,2]. 
Dos series de recomendaciones especificas, segun las circunstancias de la exposicion, han sido hechas, si bien la diferencia entre ambas puede ser discutible en lo relativo a evitar o prevenir una infeccion confirmada despues de una exposicion al VIH (o, por supuesto, al VHC o VHB). Como senalan los autores, la profilaxis postexposicion (PEP) se aplica de forma sistematica a los profesionales sanitarios en casi todos los paises, incluido EE UU, pero no en caso de exposiciones sexuales, o por uso inyectado de drogas por via parenteral, o por otras exposiciones no ocupacionales al VIH. En el caso de una exposicion profesional al VIH, la tarea de los investigadores ha sido homogeneizar las distintas recomendaciones y estrategias nacionales. Para las exposiciones no profesionales, el proposito fue establecer unas recomendaciones europeas, dado que existen pocas recomendaciones nacionales. 
Ambos articulos muestran que la justificacion, las circunstancias, el manejo y la eleccion del tratamiento en una PEP son muy similares en ambas situaciones.
Comparison of Endoscopic Ultrasound–Fine-Needle Aspiration and Endoscopic Ultrasound–Fine-Needle Biopsy for Solid Lesions in a Multicenter, Randomized Trial
Authors: Satish Nagula, Kamron Pourmand, Harry Aslanian, Juan Carlos Bucobo, Tamas A. Gonda, Susana Gonzalez, Adam Goodman, Seth A. Gross, Sammy Ho, Christopher J. DiMaio, Michelle K. Kim, Shireen Pais, John M. Poneros, David H. Robbins, Felice Schnoll-Sussman, Amrita Sethi, Jonathan M. Buscaglia
Journal: Clinical Gastroenterology and Hepatology (2017)
Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): A mono-institutional retrospective study
Authors: G. Lombardi, M.A. Ferrara, A. Pambuku, M. Lorusso, F. Boaretto, F. Schiavi, L. Biasini, F. Azzolin, G. Opocher, S. Zovato, V. Zagonel
Journal: Annals of Oncology (2017)
Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers
Authors: O. Caba, A.L. Irigoyen, C. Jimenez-Luna, M. Benavides, F.M. Ortuño, C. Guillen-Ponce, I. Rojas, E. Aranda Aguilar, J.C. Prados
Journal: Annals of Oncology (2017)
HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs): A retrospective analysis
Authors: A. Lamarca, S. Galdy, S. Moghadam, J. Rogan, M.G. McNamara, R.A. Hubner, A. Cramer, J.W. Valle
Journal: Annals of Oncology (2017)
GW28-e0940 Comparison of drug-coated balloon versus drug-eluting stent in patients with drug-eluting stent in-stent restenosis: Insight from randomized controlled trials
Authors: Wenhao Liu, Shaohua Wang, Chengzhang Xu, Haifeng Zhang, Yongqing Lin, Yangxin Chen, Jingfeng Wang
Journal: Journal of the American College of Cardiology (2017)
Luma is not essential for murine cardiac development and function
Authors: Matthew J Stroud, Xi Fang, Jianlin Zhang, Nuno Guimarães-Camboa, Jennifer Veevers, Nancy D Dalton, Yusu Gu, William H Bradford, Kirk L Peterson, Sylvia M Evans, Larry Gerace, Ju Chen
Journal: Cardiovascular Research (2017)

Luma is a recently discovered, evolutionarily conserved protein expressed in mammalian heart, which is associated with the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex. The LINC complex structurally integrates the nucleus and the cytoplasm and plays a critical role in mechanotransduction across the nuclear envelope. Mutations in several LINC components in both humans and mice result in various cardiomyopathies, implying they play essential, non-redundant roles. A single amino acid substitution of serine 358 to leucine (S358L) in Luma is the unequivocal cause of a distinct form of arrhythmogenic cardiomyopathy. However, the role of Luma in heart has remained obscure. In addition, it also remains to be determined how the S358L mutation in Luma leads to cardiomyopathy.To determine the role of Luma in the heart, we first determined the expression pattern of Luma in mouse heart. Luma was sporadically expressed in cardiomyocytes throughout the heart, but was highly and uniformly expressed in cardiac fibroblasts and vascular smooth muscle cells. We also generated germline null Luma mice and discovered that germline null mutants were viable and exhibited normal cardiac function. Luma null mice also responded normally to pressure overload induced by transverse aortic constriction. In addition, localization and expression of other LINC complex components in both cardiac myocytes and fibroblasts was unaffected by global loss of Luma. Furthermore, we also generated and characterized Luma S358L knock-in mice, which displayed normal cardiac function and morphology.Our data suggest that Luma is dispensable for murine cardiac development and function and that the Luma S358L mutation alone may not cause cardiomyopathy in mice.
Reduced-intensity bevacizumab in progressive glioblastoma multiforme (GBM) is associated with similar overall survival versus standard-dosing
Authors: J.P. Gleeson, N. Keegan, E. Harrold, D. Kamel, N. Karadawi, E. Mammadov, D. Kelly, C. O'Leary, P. O'Halloran, K. Egan, S. Molloy, S. Mac Nally, B.T. Hennessy, O.S. Breathnach, W. Grogan, P.G. Morris
Journal: Annals of Oncology (2017)
Treatment of recurrent glioblastoma (GB) after radiotherapy (RT) and temozolomide (TMZ): A retrospective analysis of the GLIOCAT study
Authors: M. Gil-Gil, J.M. Velarde, M. Martinez-Garcia, O. Gallego, S. del Barco, E. Pineda, C. Mesia, A. Estival, N. Vilariño, J. Marruecos, E. Verger, J. Craven, R. Fuentes, A. Lucas, M. Macià, C. Carrato, N. Vidal, R. Velasco, S. Villa, C. Balana
Journal: Annals of Oncology (2017)

Background: There is no standard treatment in recurrent GB and overall survival (OS) ranges from 3 to 9 months (m). The aim of this study was to identify clinical or biological factors that guide the best therapeutic strategy. Methods: We identified 397 patients (Pts) from GLIOCAT database (432 patients uniformly treated with Stupp's regimen) who had recurrent GB: 250 Pts received 1 or more active treatment (TT) and 147 Pts didn't. We analysed clinical and molecular characteristics, treatments received, OS and progression-free survival (PFS). Results: The median TT lines after recurrence was 1 (0-5). At 1st recurrence surgery was performed in 51 (30 alone), RT in 8 and systemic therapy (ST) in 208 Pts (189 without any local TT): Bevazicumab (BV) ± Irinotecan (IR) 90; clinical trial (CT) 42; TMZ 27; Nitrosoureas (NU) 27]. Pts without any TT were older (p < 0.001), had worse KPS (p < 0.001), worse Mini-Mental (MM) (p = 0.003), more biopsies than resection (p < 0.001) and did not complete the 6 cycles of adjuvant TMZ (p < 0.001) analyzed by χ2. In the multivariate analysis the only two variables statistically significant for OS were receiving treatment at progression (OS 2.5m vs 10.6m p < 0.0001) and biopsy versus partial or complete resection at diagnosis (p = 0.005). Methylated MGMT tumours had a worse OS from the time of relapse, irrespective of the treatment administered (p = 0.014). Salvage surgery did not present better OS (p = 0.69). 230 Pts had a 2nd recurrence: 128 received a 2nd line TT (surgery 8; RT 5 and ST 114: BV ± IR 42; NU 31; TMZ 19; CT 11; other 11). 110 Pts had a 3th recurrence: 42 received a 3th line. Pts who received TT had better OS than those who did not receive TT in 2nd (p < 0.0001) and in 3th recurrence (p < 0.0001) evaluated by Log rank test (Kaplan-Meier). BV was the TT that obtained the highest median PFS in the 1st and 2nd relapse. There were no significant differences in OS between the different TT regimens (median OS from relapse 7.7 m). Conclusions: Pts who received TT at recurrence offered a better OS in multivariate analysis. Pts undergoing surgery did not present better OS than those who only received ST. MGMT methylation is not a predictor of better OS in recurrence. Pts treated with BV had longer PFS but not OS. Legal entity responsible for the study: GLIOCAT Funding: None Disclosure: M. Gil-Gil: Membership on a Roche advisory board. All other authors have declared no conflicts of interest.
Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)
Authors: M. Lambertini, C. Campbell, J. Bines, L. Korde, M.A. Izquierdo Delso, D. Fumagalli, K. Pritchard, A. Wolff, C. Jackisch, I. Lang, M. Untch, I. Smith, F.M. Boyle, B. Xu, C.H. Barrios, J. Baselga, A. Moreno-Aspitia, M. Piccart, R. Gelber, E. De Azambuja
Journal: Annals of Oncology (2017)
Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer
Authors: Hee-Joo Choi, Hyeong-Seok Joo, Hee-Young Won, Kyueng-Whan Min, Hyung-Yong Kim, Taekwon Son, Young-Ha Oh, Jeong-Yeon Lee, Gu Kong
Journal: JNCI Journal of the National Cancer Institute (2017)

Despite the benefit of endocrine therapy, acquired resistance during or after treatment still remains a major challenge in estrogen receptor (ER)–positive breast cancer. We investigated the potential role of histone demethylase retinoblastoma-binding protein 2 (RBP2) in endocrine therapy resistance of breast cancer. Survival of breast cancer patients according to RBP2 expression was analyzed in three different breast cancer cohorts including METABRIC (n = 1980) and KM plotter (n = 1764). RBP2-mediated tamoxifen resistance was confirmed by in vitro sulforhodamine B (SRB) colorimetric, colony-forming assays, and in vivo xenograft models (n = 8 per group). RNA-seq analysis and receptor tyrosine kinase assay were performed to identify the tamoxifen resistance mechanism by RBP2. All statistical tests were two-sided. RBP2 was associated with poor prognosis to tamoxifen therapy in ER-positive breast cancer (P = .04 in HYU cohort, P = .02 in KM plotter, P = .007 in METABRIC, log-rank test). Furthermore, RBP2 expression was elevated in patients with tamoxifen-resistant breast cancer (P = .04, chi-square test). Knockdown of RBP2 conferred tamoxifen sensitivity, whereas overexpression of RBP2 induced tamoxifen resistance in vitro and in vivo (MCF7 xenograft: tamoxifen-treated control, mean [SD] tumor volume = 70.8 [27.9] mm3, vs tamoxifen-treated RBP2, mean [SD] tumor volume = 387.9 [85.1] mm3, P < .001). Mechanistically, RBP2 cooperated with ER co-activators and corepressors and regulated several tamoxifen resistance–associated genes, including NRIP1, CCND1, and IGFBP4 and IGFBP5. Furthermore, epigenetic silencing of IGFBP4/5 by RBP2-ER-NRIP1-HDAC1 complex led to insulin-like growth factor–1 receptor (IGF1R) activation. RBP2 also increased IGF1R-ErbB crosstalk and subsequent PI3K-AKT activation via demethylase activity–independent ErbB protein stabilization. Combinational treatment with tamoxifen and PI3K inhibitor could overcome RBP2-mediated tamoxifen resistance (RBP2-overexpressing cells: % cell viability [SD], tamoxifen = 89.0 [3.8]%, vs tamoxifen with BKM120 = 41.3 [5.6]%, P < .001). RBP2 activates ER-IGF1R-ErbB signaling cascade in multiple ways to induce tamoxifen resistance, suggesting that RBP2 is a potential therapeutic target for ER-driven cancer.
Le botulisme en Europe
Authors: H Therre
Journal: Eurosurveillance (1999)

La premiere description de la toxine botulique en tant que puissant neurotoxique date de la fin du 18eme siecle. On distingue actuellement trois formes principales de botulisme, distinctes sur le plan clinique et epidemiologique : le botulisme d’origine alimentaire qui resulte de l’ingestion d’un aliment contenant la toxine, le botulisme du nourrisson lie a la formation endogene de toxines apres germination des spores de Clostridium botulinum dans l’intestin et le botulisme par blessure cause par le developpement de C. botulinum et la production de toxine au niveau de plaies contaminees. On connait sept types de C. botulinum, qui different par les proprietes antigeniques des toxines qu’elles produisent. Les types A, B, E, et plus rarement F, sont pathogenes pour l’homme (1).
Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis
Authors: Xiaoqian Liu, Gustavo C Machado, Jillian P Eyles, Varshini Ravi, David J Hunter
Journal: British Journal of Sports Medicine (2017)

Objective To investigate the efficacy and safety of dietary supplements for patients with osteoarthritis. Design An intervention systematic review with random effects meta-analysis and meta-regression. Data sources MEDLINE, EMBASE, Cochrane Register of Controlled Trials, Allied and Complementary Medicine and Cumulative Index to Nursing and Allied Health Literature were searched from inception to April 2017. Study eligibility criteria Randomised controlled trials comparing oral supplements with placebo for hand, hip or knee osteoarthritis. Results Of 20 supplements investigated in 69 eligible studies, 7 (collagen hydrolysate, passion fruit peel extract, Curcuma longa extract, Boswellia serrata extract, curcumin, pycnogenol and L-carnitine) demonstrated large (effect size &gt;0.80) and clinically important effects for pain reduction at short term. Another six (undenatured type II collagen, avocado soybean unsaponifiables, methylsulfonylmethane, diacerein, glucosamine and chondroitin) revealed statistically significant improvements on pain, but were of unclear clinical importance. Only green-lipped mussel extract and undenatured type II collagen had clinically important effects on pain at medium term. No supplements were identified with clinically important effects on pain reduction at long term. Similar results were found for physical function. Chondroitin demonstrated statistically significant, but not clinically important structural improvement (effect size −0.30, –0.42 to −0.17). There were no differences between supplements and placebo for safety outcomes, except for diacerein. The Grading of Recommendations Assessment, Development and Evaluation suggested a wide range of quality evidence from very low to high. Conclusions The overall analysis including all trials showed that supplements provided moderate and clinically meaningful treatment effects on pain and function in patients with hand, hip or knee osteoarthritis at short term, although the quality of evidence was very low. Some supplements with a limited number of studies and participants suggested large treatment effects, while widely used supplements such as glucosamine and chondroitin were either ineffective or showed small and arguably clinically unimportant treatment effects. Supplements had no clinically important effects on pain and function at medium-term and long-term follow-ups.
Death by Gun Violence—A Public Health Crisis
Authors: Howard Bauchner, Frederick P. Rivara, Robert O. Bonow, Neil M. Bressler, Mary L. (Nora) Disis, Stephan Heckers, S. Andrew Josephson, Melina R. Kibbe, Jay F. Piccirillo, Rita F. Redberg, John S. Rhee, June K. Robinson
Journal: JAMA Cardiology (2017)
GW28-e0050 Assessment 2D and 3D global longitudinal Strain of abnormal LV myocardial deformation properties Using 3D Speckle-Tracking Echocardiography in young HCM
Authors: Yang Qian, Tang Peng, Shuping Ge, Hong Wang, Xiaofeng Yang, Liwen Liu, Xiaodong Zhou
Journal: Journal of the American College of Cardiology (2017)
Molecular profiling of recurrent and metastatic salivary gland cancer to personalise cancer therapy
Authors: S. Rack, E. Darlington, S. Odedra, R. Owens, D. Sarah, B. Shah, N. Cook, F. Thistlethwaite, L. Carter, A. Hughes, J. Homer, N. Slevin, M. Krebs, R. Metcalf
Journal: Annals of Oncology (2017)
Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
Authors: T.K. Choueiri, C. Hessel, S. Halabi, B. Sanford, O. Hahn, M.D. Michaelson, M. Walsh, T. Olencki, J. Picus, E.J. Small, S. Dakhil, C. Scheffold, D.J. George, M.J. Morris
Journal: Annals of Oncology (2017)